<DOC>
	<DOCNO>NCT01190644</DOCNO>
	<brief_summary>What hematopoietic precursor compartment well hemoglobin subtypes affect dose Sotatercept ( ACE-011 ) ? Based upon similar prior study Procrit , Celgene determine goal could obtain intense 10 patient , Sotatercept ( ACE-011 ) pharmacodynamic study , complete two well know expert red cell production field .</brief_summary>
	<brief_title>Study Evaluate Effect Single Dose Sotatercept ( ACE-011 ) Red Blood Cell Mass Plasma Volume Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Men woman ≥ 18 year age . 2 . Histologically confirm diagnosis solid tumor malignancy document cytology biopsy . 3 . Presence metastatic disease . 4 . Hemoglobin value ≥ 8.0 &lt; 11.0 g/dL ( ≥ 80 &lt; 110 g/L ) . 5 . ≥ 28 day must elapse ( prior predose RBC mass / PV test ) since previous treatment erythropoiesisstimulating agent ( include concurrent treatment IV iron ) . 6 . ≥ 28 day must elapse ( prior Day 1 ) since last RBC blood transfusion receipt ≤ 2 unit blood past 56 day ( prior Day 1 ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . At time screening , subject grade ≥ 3 toxicity ( accord currently active minor version NCI CTCAE v4.0 , except follow disease related toxicity : Hematological event anemia , thrombocytopenia , neutropenia Nonhematological event nausea , vomit , fatigue , muscle bone/joint pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Red Blood Cell Mass</keyword>
	<keyword>Plasma Volume</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>